Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Common Variable Immunodeficiency 1Agammaglobulinemia 1

Interventions

pembrolizumab 521Specimen Handling 383Carboplatin 376Magnetic Resonance Spectroscopy 334Cisplatin 331Nivolumab 309Cyclophosphamide 298Radiotherapy 257Paclitaxel 254Biopsy 235Gemcitabine 234Bevacizumab 218Dexamethasone 169durvalumab 167Oxaliplatin 163Capecitabine 159Rituximab 156Fluorouracil 149venetoclax 147Docetaxel 147atezolizumab 143Drug Therapy 143Etoposide 141Doxorubicin 134Ipilimumab 129Prednisone 121Radiosurgery 120Lenalidomide 118Leucovorin 113fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hizentra × 1 year × Clear all
NCT06976476 2026-03-11

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
100 enrolled
Plasma cell

Agammaglobulinemia, Multiple Myeloma, Common Variable Immunodeficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡